Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 15;22(24):6247–6255. doi: 10.1158/1078-0432.CCR-15-2738

Fig 3.

Fig 3

Identification of MHC class II genes associated with progression-free survival (PFS) of pediatric ACT. The five MHC class II probe-sets most differentially expressed in adenomas vs. carcinomas (IPACTR cohort) were used to assess PFS in the uniformly-treated COG group of pediatric adrenocortical carcinomas (n = 34).